NCT01108861已完成4 期
The GORE VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Versus Plain Old Balloon Angioplasty (POBA) for the Treatment of Superficial Femoral Artery (SFA) In-Stent Restenosis
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 12
- 主要终点
- Primary patency at 12 months, defined as no evidence of restenosis or occlusion within the originally treated lesion based on color-flow duplex ultrasound (CFDU) and without target lesion revascularization (TLR) within 12 months.
研究概览
简要总结
This is a prospective, randomized, multi-center study recruiting patients with an in-stent restenosis in the superficial femoral artery. The safety and efficacity of the Viabahn endoprosthesis (W.L. Gore & Associates), a heparin-bonded endoprosthesis, is compared with plain old balloon angioplasty (POBA). In 4 Belgian and 2 German centers a total of 80 Patients will be recruited. Primary endpoint is primary patency at 12 months, defined as no evidence of restenosis or occlusion within the originally treated lesion based on color-flow duplex ultrasound (CFDU) measuring a peak systolic velocity ratio ≤2.5, and without target lesion revascularization (TLR) within 12 months.
In comparison to POBA, it is expected that the use of the Viabahn endoprosthesis (W.L. Gore & Associates) will result in greater 12 month primary patency of treated superficial femoral artery in-stent restenotic lesions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient presenting with lifestyle-limiting claudication, rest pain or minor tissue loss (Rutherford classification from 2 to 5)
- •Patient is willing to comply with specified follow-up evaluations at the specified times
- •Patient is >18 years old
- •Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- •Patient has a projected life-expectancy of at least 24 months
- •Noninvasive lower extremity arterial studies (resting or exercise) demonstrate ankle-brachial index ≤0.8
- •Patient is eligible for treatment with the Viabahn® Endoprosthesis (W.L. Gore)
- •Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure
- •Angiographic Inclusion Criteria
- •Restenotic or reoccluded lesion located in a stent which was previously implanted (>30 days) in the superficial femoral artery, suitable for endovascular therapy
- •Total target lesion length between 4 and 27 cm (comprising in-stent restenosis and adjacent stenotic disease)
- •Minimum of 1.0cm of healthy vessel (non-stenotic) both proximal and distal to the treatment area
- •Popliteal artery is patent at the intercondylar fossa of the femur to P3
- •Target vessel diameter visually estimated to be >4mm and <7.6 mm at the proximal and distal treatment segments within the SFA
- •Guidewire and delivery system successfully traversed lesion
- •There is angiographic evidence of at least one-vessel-runoff to the foot, that does not require intervention (<50% stenotic)
- •Exclusion criteria :
- •Untreated flow-limiting aortoiliac stenotic disease
- •Presence of a chronic total occlusion, i.e. a complete occlusion of the failed bare stent that cannot be re-opened with thrombolysis or does not allow easy passage of the guidewire by the physician
- •Any previous surgery in the target vessel
- •Severe ipsilateral common/deep femoral disease requiring surgical reintervention
- •Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment
- •Femoral or popliteal aneurysm located at the target vessel
- •Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
- •No patent tibial arteries (>50% stenosis)
- •Prior ipsilateral femoral artery bypass
- •Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 2-year life expectancy
- •Serum creatinine >2.5mg/dL within 45 days prior to study procedure unless the subject is currently on dialysis
- •Major distal amputation (above the transmetatarsal) in the study or non-study limb
- •Septicemia or bacteremia
- •Any previously known coagulation disorder, including hypercoagulability
- •Contraindication to anticoagulation or antiplatelet therapy
- •Known allergies to stent or stent graft components (nickel-titanium or ePTFE)
- •Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure
- •Patient with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
- •Currently participating in another clinical research trial, unless approved by W.L. Gore & Associates in advance of study enrolment
- •Angiographic evidence of intra-arterial thrombus or atheroembolism from inflow treatment
- •Any planned surgical intervention/procedure within 30 days of the study procedure
- •Target lesion access not performed by transfemoral approach.
排除标准
- 未提供
结局指标
主要结局
Primary patency at 12 months, defined as no evidence of restenosis or occlusion within the originally treated lesion based on color-flow duplex ultrasound (CFDU) and without target lesion revascularization (TLR) within 12 months.
时间窗: 1 year
Proportion of subjects who experience serious device-related adverse events within 30 days post-procedure
时间窗: 30 days
次要结局
- Technical success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30%.(during procedure)
- Hemodynamic primary patency rate at 1, 6, 12, 24-month follow-up.(1, 6, 12, 24-month follow-up)
- Angiographic primary patency at 12 months(1 year)
- Primary assisted patency rate at 1, 6, 12, 24-month follow-up.(1, 6, 12, 24-month follow-up)
- Secondary patency rate at 1, 6, 12, 24-month follow-up(1, 6, 12, 24-month follow-up)
- Target lesion revascularization (TLR)(entire follow-up)
- Clinical success at follow-up(at 1 day and 1, 6, 12, 24-month follow-up)
- Serious adverse events(during entire follow-up)
- Stent fracture rate at 12 months(1 year)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
3 期
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in HemodialysisHemodialysisRenal FailureNCT00737672W.L.Gore & Associates293
已完成
不适用
Treatment of Patients With Traumatic or Iatrogenic Vessel InjuriesIatrogenic Vessel InjuryNCT05183399W.L.Gore & Associates30
终止
不适用
Evaluation of GORE® VIABAHN® Endoprosthesis for Popliteal Artery AneurysmPopliteal Artery AneurysmNCT01902888W.L.Gore & Associates3
进行中（未招募）
不适用
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global RegistryPeripheral Artery DiseasePopliteal AneurysmHemodialysis AccessVisceral Artery AneurysmsTrauma InjuryNCT04907240W.L.Gore & Associates614
已完成
不适用
GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study (JPS 16-03)Peripheral Arterial DiseaseNCT04706273W.L.Gore & Associates321